Skip to main content

CytoMed Therapeutics Ltd

corporate_fare Company Profile

CytoMed Therapeutics Ltd

GDTC·NASDAQ·Life Sciences·CIK 0001873093

We are a clinical stage biopharmaceutical company focused on creating new cell-based immunotherapies to treat human cancers and degenerative diseases. Our technologies are inspired by the success of existing CAR-T cells in treating blood cancers, while addressing the limitations of applying CAR-T to solid tumors. We believe cellular immunotherapy is becoming a key part of cancer care, but current CAR-T principles are challenging to apply to other cancers, especially solid tumors. This is due to reliance on limited patient cell quality and quantity, lack of suitable surface cancer antigens and recognition systems, and the risk of cancer escaping a single antigen-targeting strategy. To overcome these challenges, we have developed two new platform technologies to manufacture "off-the-shelf" cell-based cancer immunotherapies that do not depend on patient blood cells. One platform uses healthy donor blood cells, and the other uses iPSC. These platforms and resulting product candidates utilize the multiple antigen recognition systems of NK cells and gamma delta T cells to recognize and treat a broad range of cancers. Based on these licensed proprietary platform technologies, we are developing four cellular immunotherapy product candidates: CTM-N2D, iPSC-gdNKT, CTM-GDT, and CTM-NK. CTM-N2D is our lead product candidate, consisting of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity.

CytoMed Therapeutics Ltd (NASDAQ:GDTC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for GDTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-13, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for GDTC spans SCHEDULE 13D/A, 6-K, 4, 144.

Recent high-impact activity:

  • Chairman Choo Chee Kong Buys $60.5K More CytoMed Shares, Stake Rises to 24.92%
  • CytoMed Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice
  • CytoMed Flags Going Concern, Books S$1M Director Loan in H1 2026 Report
  • Director and 10% Owner Choo Chee Kong Buys $300K More of CytoMed Therapeutics
  • Chairman Offers to Buy Shares, Invests $250K in Subsidiary R&D Amidst Financial Challenges

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
S$324.39K SGD
Net Income
-S$4M SGD
Diluted EPS
-S$0.34 SGD
Op. Cash Flow
-S$3.7M SGD
Free Cash Flow
-S$4.34M SGD
Cash & Equivalents
S$2.1M SGD
Total Debt
S$368.66K SGD
Debt / Equity
0.05×
Net Margin
-12.32×
Shares Outstanding
11.83M sh
Source: 20-F · filed 2026-03-31 · accession 0001493152-26-013813

Short Interest & Short Volume

1.81 days to cover

FINRA reported short interest of 17,603 shares in GDTC as of the October 30, 2026 settlement, a 9.0% decrease from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 25.1% of GDTC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,603 shares as of October 30, 2026
Change vs prior period▼ 9.0%
Days to cover1.81 at avg daily volume of 9,745
Daily short volume (FINRA facilities)25.1% of 10,021 shares on November 20, 2026
5-day average short volume36.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

GDTC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with G →
$0.755 -3.80% today
52-week range · as of 2026-10-13 $0.6801 – $3.68
Market cap
$9.29M
Volume
15.1K (1.1× avg)
3-mo avg 13.9K
Live data · 2026-11-21 07:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GDTC - Latest Insights

GDTC
Oct 13, 2026, 6:14 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.8114
Real-time Price: $0.755 info
Change: -$0.0564 (-7%) info
Market Cap: $9.286M info
GDTC
Oct 09, 2026, 7:43 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.8114
Real-time Price: $0.755 info
Change: -$0.0564 (-7%) info
Market Cap: $9.286M info
GDTC
Sep 30, 2026, 9:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.9197
Real-time Price: $0.755 info
Change: -$0.1647 (-18%) info
Market Cap: $9.286M info
GDTC
Jul 24, 2026, 12:33 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $0.990
Real-time Price: $0.755 info
Change: -$0.235 (-24%) info
Market Cap: $9.286M info
GDTC
Jun 23, 2026, 12:14 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.996
Real-time Price: $0.755 info
Change: -$0.241 (-24%) info
Market Cap: $9.286M info
GDTC
Jun 15, 2026, 6:15 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $0.755 info
Change: -$0.385 (-34%) info
Market Cap: $9.286M info
GDTC
Jun 03, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $0.755 info
Change: -$0.425 (-36%) info
Market Cap: $9.286M info
GDTC
May 15, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.9499
Real-time Price: $0.755 info
Change: -$0.1949 (-21%) info
Market Cap: $9.286M info
GDTC
May 13, 2026, 10:03 AM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $0.750
Real-time Price: $0.755 info
Change: +$0.0050 (+0.67%) info
Market Cap: $9.286M info
GDTC
Apr 14, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.9999
Real-time Price: $0.755 info
Change: -$0.2449 (-24%) info
Market Cap: $9.286M info
GDTC
Mar 31, 2026, 9:36 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.02
Real-time Price: $0.755 info
Change: -$0.265 (-26%) info
Market Cap: $9.286M info
GDTC
Mar 31, 2026, 8:01 AM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $1.03
Real-time Price: $0.755 info
Change: -$0.275 (-27%) info
Market Cap: $9.286M info
GDTC
Feb 12, 2026, 9:03 AM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $0.970
Real-time Price: $0.755 info
Change: -$0.215 (-22%) info
Market Cap: $9.286M info
GDTC
Jan 28, 2026, 11:41 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.7817
Real-time Price: $0.755 info
Change: -$0.0267 (-3%) info
Market Cap: $9.286M info
GDTC
Jan 13, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.755 info
Change: -$0.475 (-39%) info
Market Cap: $9.286M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets